We pursue two broad areas of research. One area is understanding molecular mechanisms that regulate hemangiogenesis, a process by which hematopoietic and endothelial cells develop. We utilize the in vitro differentiation model of embryonic stem cells and mouse models to understand hemangiogenic lineage specification. We are currently focusing on the role of Etv2, Vegf, and Vegfr2 and their interaction in the hemangiogenic lineage commitment and the role of epigenetics in hematopoietic and endothelial cell development. The second area of research is understanding the relationship between tumor angiogenesis and tumor immunity. We have shown that tumor angiogenesis and tumor immunity are inversely correlated. Currently, we focus on targeting angiogenesis to improve tumor immunity and enhance the efficacy of immunotherapies. By normalizing the tumor vasculature, reducing immunosuppression, and improving immune cell access to tumors, this strategy can significantly boost the effectiveness of immunotherapies and lead to better clinical outcomes for patients.